Melanotan (MT)-II (Synonyms: 美拉诺坦 (MT)-II)

目录号: HY-P0267 纯度: 99.65%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Melanotan (MT)-II是一种合成的黑皮质素 (melanocortin) 受体激动剂。它是可注射用的多肽荷尔蒙，可促进晒黑。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

Melanotan (MT)-II Chemical Structure

CAS No. : 121062-08-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥300	In-stock
5 mg	￥600	In-stock
10 mg	￥900	In-stock
25 mg	￥1500	In-stock
50 mg	￥2400	In-stock
100 mg	￥3900	In-stock
200 mg		询价
500 mg		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 1 篇科研文献

•Cell Rep. 2024 Nov 19;43(12):114983. [Abstract]

Melanotan (MT)-II 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Melanocortin Receptor 亚型特异性产品:

查看所有亚型

MC1R MC3R MC2R MC4R MC5R

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Melanotan (MT)-II, a synthetic melanocortin receptor agonist, is an injectable peptide hormone used to promote tanning.

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-375	EC₅₀	110 nM Compound: MT-II	Agonist activity at human MC1 receptor expressed in A375 cells assessed as intracellular cAMP accumulation using [3H]-cAMP by luminescence counting Agonist activity at human MC1 receptor expressed in A375 cells assessed as intracellular cAMP accumulation using [3H]-cAMP by luminescence counting	[PMID: 26218460]
A-375	IC₅₀	6.7 nM Compound: MT-II	Antagonist activity at human MC1 receptor expressed in A375 cells assessed as inhibition of MT-II-induced intracellular cAMP accumulation using [3H]-cAMP by luminescence counting Antagonist activity at human MC1 receptor expressed in A375 cells assessed as inhibition of MT-II-induced intracellular cAMP accumulation using [3H]-cAMP by luminescence counting	[PMID: 26218460]
HEK293	EC₅₀	0.021 nM Compound: MTII	Agonist activity at mouse MC1R expressed in HEK293 cells by beta-galactosidase assay Agonist activity at mouse MC1R expressed in HEK293 cells by beta-galactosidase assay	[PMID: 15615519]
HEK293	EC₅₀	0.03 nM Compound: MT-II	Activity at mouse MC1R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay Activity at mouse MC1R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay	[PMID: 25347033]
HEK293	EC₅₀	0.04 nM Compound: MTII	Agonist activity at mouse MC4R expressed in HEK293 cells by beta-galactosidase assay Agonist activity at mouse MC4R expressed in HEK293 cells by beta-galactosidase assay	[PMID: 15615519]
HEK293	EC₅₀	0.05 nM Compound: MTII	Agonist activity at mouse melanocortin-4 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay Agonist activity at mouse melanocortin-4 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay	[PMID: 25699138]
HEK293	EC₅₀	0.06 nM Compound: MT-II	Activity at mouse MC4R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay Activity at mouse MC4R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay	[PMID: 25347033]
HEK293	EC₅₀	0.17 nM Compound: MTII	Agonist activity at mouse MC3R expressed in HEK293 cells by beta-galactosidase assay Agonist activity at mouse MC3R expressed in HEK293 cells by beta-galactosidase assay	[PMID: 15615519]
HEK293	EC₅₀	0.18 nM Compound: MT-II	Activity at mouse MC3R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay Activity at mouse MC3R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay	[PMID: 25347033]
HEK293	EC₅₀	0.18 nM Compound: MTII	Agonist activity at mouse MC5R expressed in HEK293 cells by beta-galactosidase assay Agonist activity at mouse MC5R expressed in HEK293 cells by beta-galactosidase assay	[PMID: 15615519]
HEK293	EC₅₀	0.19 nM Compound: MT-II	Activity at mouse MC5R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay Activity at mouse MC5R expressed in HEK293 cells assessed as cAMP accumulation by CRE/beta-galactosidase reporter gene assay	[PMID: 25347033]
HEK293	EC₅₀	0.22 nM Compound: MTII	Agonist activity at mouse melanocortin-1 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay Agonist activity at mouse melanocortin-1 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay	[PMID: 25699138]
HEK293	EC₅₀	0.3 nM Compound: 17	Activity against hMC1R transfected in HEK293 cells by intracellular cAMP accumulation Activity against hMC1R transfected in HEK293 cells by intracellular cAMP accumulation	[PMID: 16539382]
HEK293	EC₅₀	0.35 nM Compound: MTII	Agonist activity at mouse melanocortin-3 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay Agonist activity at mouse melanocortin-3 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay	[PMID: 25699138]
HEK293	EC₅₀	0.57 nM Compound: MTII	Agonist activity at mouse melanocortin-5 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay Agonist activity at mouse melanocortin-5 receptor transfected in HEK293 cells after 6 hrs by beta-galactosidase reporter gene assay	[PMID: 25699138]
HEK293	IC₅₀	1 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC1 receptor expressed in HEK293 cells by gamma counting analysis Displacement of [125I]-NDP-alpha-MSH from human MC1 receptor expressed in HEK293 cells by gamma counting analysis	[PMID: 25699148]
HEK293	EC₅₀	1 nM Compound: MT-II	Activity at human MC1R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation Activity at human MC1R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation	[PMID: 16931008]
HEK293	EC₅₀	1.02 nM Compound: MT-II	Activity at human MC1 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter Activity at human MC1 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter	[PMID: 25699148]
HEK293	IC₅₀	1.1 nM Compound: MT-II	Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 4 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 4 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis	[PMID: 26599352]
HEK293	IC₅₀	1.2 nM Compound: MT-II	Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 1 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 1 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis	[PMID: 26599352]
HEK293	IC₅₀	1.2 nM Compound: MT-II	Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 3 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 3 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis	[PMID: 26599352]
HEK293	EC₅₀	1.8 nM Compound: MT-II	Agonist activity at human melanocortin 1 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX Agonist activity at human melanocortin 1 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX	[PMID: 26599352]
HEK293	EC₅₀	1.8 nM Compound: MT-II	Agonist activity at human melanocortin 3 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX Agonist activity at human melanocortin 3 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX	[PMID: 26599352]
HEK293	EC₅₀	1.9 nM Compound: 17	Activity against hMC3R transfected in HEK293 cells by intracellular cAMP accumulation Activity against hMC3R transfected in HEK293 cells by intracellular cAMP accumulation	[PMID: 16539382]
HEK293	IC₅₀	2 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC3 receptor expressed in HEK293 cells by gamma counting analysis Displacement of [125I]-NDP-alpha-MSH from human MC3 receptor expressed in HEK293 cells by gamma counting analysis	[PMID: 25699148]
HEK293	EC₅₀	2.1 nM Compound: MT-II	Agonist activity at human MC4 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter Agonist activity at human MC4 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter	[PMID: 25699148]
HEK293	IC₅₀	2.3 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC1R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting Displacement of [125I]-NDP-alpha-MSH from human MC1R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting	[PMID: 21486697]
HEK293	IC₅₀	2.3 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC4R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting Displacement of [125I]-NDP-alpha-MSH from human MC4R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting	[PMID: 21486697]
HEK293	IC₅₀	2.3 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC4 receptor expressed in HEK293 cells by gamma counting analysis Displacement of [125I]-NDP-alpha-MSH from human MC4 receptor expressed in HEK293 cells by gamma counting analysis	[PMID: 25699148]
HEK293	EC₅₀	2.3 nM Compound: MT-II	Activity at human MC4R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation Activity at human MC4R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation	[PMID: 16931008]
HEK293	EC₅₀	2.4 nM Compound: MT-II	Activity at human MC3R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation Activity at human MC3R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation	[PMID: 16931008]
HEK293	EC₅₀	2.9 nM Compound: MT-II	Agonist activity at human melanocortin 4 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX Agonist activity at human melanocortin 4 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX	[PMID: 26599352]
HEK293	EC₅₀	2.9 nM Compound: 17	Activity against hMC4R transfected in HEK293 cells by intracellular cAMP accumulation Activity against hMC4R transfected in HEK293 cells by intracellular cAMP accumulation	[PMID: 16539382]
HEK293	EC₅₀	3.1 nM Compound: MT-II	Agonist activity at EYFP-fused human MC4R expressed in HEK293 cells assessed as increase in cAMP accumulation after 30 mins by luminescent enzymatic complementation based assay Agonist activity at EYFP-fused human MC4R expressed in HEK293 cells assessed as increase in cAMP accumulation after 30 mins by luminescent enzymatic complementation based assay	[PMID: 28972753]
HEK293	EC₅₀	3.3 nM Compound: MT-II	Agonist activity at human melanocortin 5 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX Agonist activity at human melanocortin 5 receptor expressed in HEK293 cells assessed as intracellular cAMP accumulation incubated for 3 mins in presence of IBMX	[PMID: 26599352]
HEK293	EC₅₀	3.3 nM Compound: 17	Activity against hMC5R transfected in HEK293 cells by intracellular cAMP accumulation Activity against hMC5R transfected in HEK293 cells by intracellular cAMP accumulation	[PMID: 16539382]
HEK293	EC₅₀	33.9 nM Compound: MT-II	Agonist activity at EYFP-fused human MC3R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay Agonist activity at EYFP-fused human MC3R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay	[PMID: 28972753]
HEK293	EC₅₀	33.9 nM Compound: MT-II	Agonist activity at EYFP-fused human MC5R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay Agonist activity at EYFP-fused human MC5R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay	[PMID: 28972753]
HEK293	IC₅₀	4.2 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC5R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting Displacement of [125I]-NDP-alpha-MSH from human MC5R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting	[PMID: 21486697]
HEK293	IC₅₀	4.2 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC5 receptor expressed in HEK293 cells by gamma counting analysis Displacement of [125I]-NDP-alpha-MSH from human MC5 receptor expressed in HEK293 cells by gamma counting analysis	[PMID: 25699148]
HEK293	EC₅₀	5.1 nM Compound: MT-II	Activity at human MC3 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter Activity at human MC3 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter	[PMID: 25699148]
HEK293	EC₅₀	5.7 nM Compound: MT-II	Antagonist activity at human MC5 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter Antagonist activity at human MC5 receptor expressed in HEK293 cells assessed as cAMP accumulation by luminescence counter	[PMID: 25699148]
HEK293	IC₅₀	7.5 nM Compound: MT-II	Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 5 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis Displacement of 125I-labeled [Nle4,DPhe7]-alpha-MSH from human melanocortin 5 receptor expressed in HEK293 cells incubated for 40 mins by gamma counting analysis	[PMID: 26599352]
HEK293	IC₅₀	8 nM Compound: MT-II	Displacement of [125I]-NDP-alpha-MSH from human MC3R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting Displacement of [125I]-NDP-alpha-MSH from human MC3R expressed in HEK293 cells after 40 mins by Wallac 1470 gamma counting	[PMID: 21486697]
HEK293	EC₅₀	8 nM Compound: MT-II	Activity at human MC5R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation Activity at human MC5R expressed in HEK293 cells assessed by measuring intracellular cAMP accumulation	[PMID: 16931008]
HEK293	EC₅₀	8.6 nM Compound: MT-II	Agonist activity at EYFP-fused human MC4R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay Agonist activity at EYFP-fused human MC4R expressed in HEK293 cells after 16 to 20 hrs by CRE-driven reporter assay	[PMID: 28972753]

体外研究
(In Vitro)

Melanotan (MT)-II 是一种有效的非选择性黑皮质素受体激动剂，对 MC1、MC3、MC4 和 MC5 受体亚型具有高亲和力，这些亚型参与许多生理系统的调节，例如色素系统、能量稳态、性功能、免疫系统、炎症和心血管系统^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Melanotan (MT)-II 通过引发勃起事件和缩短第一次勃起事件发生的潜伏期，对勃起施加剂量依赖性诱导剂活性。静脉注射黑素素 (MT)-II (1 mg/kg) 后海绵体神经刺激引起的勃起反应增加，从而对勃起产生促进作用^[2]。
Melanotan (MT)-II 促进周围神经再生并在大鼠中具有神经保护特性。Melanotan (MT)-II 剂量为 20 μg/kg 每 48 小时，皮下注射时，显著增强大鼠坐骨神经挤压损伤后感觉功能的恢复，但剂量为 2 或 50 μg/kg 时无效果^[3]。
Melanotan (MT)-II 是勃起功能障碍男性阴茎勃起的有效启动剂^[4]。
Melanotan (MT)-II 在小鼠模型中减少食物摄入量和体重并引发产热反应^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1024.18

Formula

C₅₀H₆₉N₁₅O₉

CAS 号

121062-08-6

性状

固体

颜色

White to off-white

Sequence

Ac-{Nle}-Asp-His-{d-Phe}-Arg-Trp-Lys-NH2, (2→7)-lactam

Sequence Shortening

Ac-{Nle}-DH-{d-Phe}-RWK-NH2, (2→7)-lactam

中文名称

美拉诺坦 (MT)-II

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

细胞实验：

H₂O 中的溶解度 : 6.67 mg/mL (6.51 mM; 超声助溶)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.9764 mL	4.8820 mL	9.7639 mL
5 mM	0.1953 mL	0.9764 mL	1.9528 mL
10 mM	---	---	---

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。

纯度 & 产品资料

纯度: 99.65%

选择批次：

Data Sheet (634 KB) SDS (252 KB)

COA (295 KB) LCMS (98 KB) 元素分析报告 (219 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Breindahl T, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015 Feb;7(2):164-72. [Content Brief]

[2]. Giuliano F, et al. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301. [Content Brief]

[3]. Ter Laak MP, et al. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur J Pharmacol. 2003 Feb 21;462(1-3):179-83. [Content Brief]

[4]. Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. [Content Brief]

[5]. De Jonghe BC, et al. Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency. Am J Physiol Endocrinol Metab. 2012 Sep 1;303(5):E644-51. [Content Brief]

Animal Administration ^[2]^[5]	Rats: To investigate the inducer activity on erection, melanotan (MT)-II or vehicle (saline) is acutely injected i.v., i.t. or within the PVN after a 5 min baseline recording period is obtained. ICP and MAP are then recorded for a 60 min period after saline or melanotan (MT)-II delivery. I.v. injections (three doses; 0.1, 0.3, and 1 mg/kg in saline) are performed with a catheter inserted in the jugular vein^[2]. Mice: Melanotan (MT)-II (0.1 and 0.2 nM) or vehicle (artificial cerebrospinal fluid) is administered. SPA is recorded continuously every 5 min. Food intake measurements are taken 6 and 24 h postinjection. Body weight is measured every 24 h. Chow and water are available ad libitum. A 48-h interval occurrs between drug treatments^[5]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Breindahl T, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015 Feb;7(2):164-72. [Content Brief] [2]. Giuliano F, et al. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301. [Content Brief] [3]. Ter Laak MP, et al. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur J Pharmacol. 2003 Feb 21;462(1-3):179-83. [Content Brief] [4]. Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. [Content Brief] [5]. De Jonghe BC, et al. Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency. Am J Physiol Endocrinol Metab. 2012 Sep 1;303(5):E644-51. [Content Brief]

Animal Administration
^[2]^[5]

Rats: To investigate the inducer activity on erection, melanotan (MT)-II or vehicle (saline) is acutely injected i.v., i.t. or within the PVN after a 5 min baseline recording period is obtained. ICP and MAP are then recorded for a 60 min period after saline or melanotan (MT)-II delivery. I.v. injections (three doses; 0.1, 0.3, and 1 mg/kg in saline) are performed with a catheter inserted in the jugular vein^[2].

Mice: Melanotan (MT)-II (0.1 and 0.2 nM) or vehicle (artificial cerebrospinal fluid) is administered. SPA is recorded continuously every 5 min. Food intake measurements are taken 6 and 24 h postinjection. Body weight is measured every 24 h. Chow and water are available ad libitum. A 48-h interval occurrs between drug treatments^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Breindahl T, et al. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. Drug Test Anal. 2015 Feb;7(2):164-72. [Content Brief]

[2]. Giuliano F, et al. Melanotan-II: Investigation of the inducer and facilitator effects on penile erection in anaesthetized rat. Neuroscience. 2006;138(1):293-301. [Content Brief]

[3]. Ter Laak MP, et al. The potent melanocortin receptor agonist melanotan-II promotes peripheral nerve regeneration and has neuroprotective properties in the rat. Eur J Pharmacol. 2003 Feb 21;462(1-3):179-83. [Content Brief]

[4]. Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000 Oct;12 Suppl 4:S74-9. [Content Brief]

[5]. De Jonghe BC, et al. Food intake reductions and increases in energetic responses by hindbrain leptin and melanotan II are enhanced in mice with POMC-specific PTP1B deficiency. Am J Physiol Endocrinol Metab. 2012 Sep 1;303(5):E644-51. [Content Brief]

Melanotan (MT)-II 相关分类

Neurological Disease

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.9764 mL	4.8820 mL	9.7639 mL	24.4098 mL
H₂O	5 mM	0.1953 mL	0.9764 mL	1.9528 mL	4.8820 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Melanotan (MT)-II121062-08-6美拉诺坦 (MT)-IIMelanocortin ReceptorMC ReceptorInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Melanotan (MT)-II (Synonyms: 美拉诺坦 (MT)-II)

Customer Review

MCE 顾客使用本产品发表的 1 篇科研文献

Melanotan (MT)-II 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Melanocortin Receptor 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Melanotan (MT)-II 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Melanotan (MT)-II (Synonyms: 美拉诺坦 (MT)-II)

Customer Review

Melanotan (MT)-II 相关抗体

MCE 顾客使用本产品发表的 1 篇科研文献

Melanotan (MT)-II 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 Melanocortin Receptor 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Melanotan (MT)-II 相关抗体:

摩尔计算器

稀释计算器

Melanotan (MT)-II 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z